
No Recommendation on Benefits and Harms of Glaucoma Screening
Based on a review of almost 100 trials and studies, researchers determined that the available evidence was too limited to support or oppose primary open-angle glaucoma screening in adults.
Based on a review of almost 100 trials and studies, researchers determined that the available evidence was too limited to support or oppose primary open-angle glaucoma screening in adults.
The US Preventive Services Task Force (USPSTF) issued a
“Glaucoma is a very serious disease for many Americans, but gaps in the available evidence on the value of screening prevent us from making a recommendation,” task force co-vice chairman Albert Siu, MD, MPH, said in a
In advance of its recommendation, the USPSTF asked researchers to review evidence regarding open-angle glaucoma treatments and their associated harms. The
The researchers analyzed 75 randomized, controlled trials and 24 observational studies. They concluded that no specific treatment option—surgical, medical, or laser—best prevented visual disability and improved patient-reported outcomes. They determined that the available evidence is simply too sparse and inconclusive to be certain.
In its draft statement, the task force identified a number of research needs. In particular, it indicated that research documenting patient-reported outcome and visual impairment should be a high priority.
The USPSTF, an independent panel of non-federal experts in prevention and evidence-based medicine, makes recommendations regarding a wide range of clinical preventive health care services. The task force is composed of primary care providers, including internists, nurses, and health behavior specialists.
Ms. Wick is a visiting professor at the University of Connecticut School of Pharmacy and a freelance writer from Virginia.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.